# US 2017/0254812 A1 · Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (vegf)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0254812 A1
- Document ID: US20170254812A1
- Status: Published application
- Kind: A1
- Application number: 15/115,902
- Filed: 2015-02-03
- Published: 2017-09-07
- Earliest claimed: 2014-02-04
- Assignees: Celltrend GmbH
- Applicants: Celltrend GmbH
- Inventors: Harald HEIDECKE; Kai SCHULZE-FORSTER
- Web page: https://patentgrep.com/patent/US20170254812A1

## CPC

- G01N 33/57545: of the ovaries
- A61P 35/00: Antineoplastic agents
- C07K 14/515: Angiogenesic factors; Angiogenin
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/475: Assays involving growth factors
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.

## Claims

### Claim 1

A method for diagnosis of cancer, comprising
(i) determining a level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed,
(ii) comparing the determined level in the sample to a control level of VEGF antibodies derived from subjects without cancer;
wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein a level of antibodies against VEGF in the sample from the subject to be diagnosed of less than 0.9 fold as compared to the control level from subjects without cancer is indicative for the presence of cancer.

### Claim 3

A method for diagnosis of cancer, wherein the level of antibodies against vascular endothelial growth factor (VEGF) is determined in a sample from a subject to be diagnosed and wherein a level of anti-VEGF antibodies below 14 units/ml is indicative for cancer.

### Claim 4

A method for predicting whether a subject to be treated for cancer with a drug will respond to said treatment comprising
(i) determining a level of antibodies against vascular endothelial growth factor (VEGF) in a sample from said subject to be treated,
(ii) comparing the determined level in the sample to either one or both of a first and second VEGF antibody control level,
a) wherein the first VEGF antibody control level is derived from subjects responding to said treatment, and
b) wherein the second VEGF antibody control level is derived from a subject not responding to said treatment,
wherein a decreased level in the sample from the subject to be treated as compared to the first VEGF antibody control level and/or an equal level as compared to the second VEGF antibody control level is indicative for a non-response of said subject to said treatment, and wherein an increased level in the sample from the subject to be treated as compared to the second VEGF antibody control level and/or an equal level as compared to the first VEGF antibody control level is indicative for a response of said subject to said treatment.

### Claim 5 (depends on 4)

The method according to claim 4, wherein a level of antibodies against VEGF in the sample from the subject to be treated of less than 0.9 fold as compared to the first VEGF antibody control level is indicative for a non-response of said subject to said treatment, and/or a level of antibodies against VEGF in the sample from the subject to be treated of more than 1.5 fold as compared to the second VEGF antibody control level is indicative for a response of said subject to said treatment.

### Claim 6

A method for the prediction of risk stratification for relapse of cancer and/or mortality in a patient to be treated or being treated for cancer with a drug, the method comprising
(i) determining a level of antibodies against vascular endothelial growth factor (VEGF) in a sample from said subject to be treated,
(ii) comparing the determined level in the sample to either one or both of a first and second VEGF antibody control level, wherein
a) the first VEGF antibody control level is derived from subjects not showing relapse of cancer or mortality after treatment with said drug, and
b) the second VEGF antibody control level is derived from subjects showing relapse of cancer or mortality after treatment with said drug,
wherein a decreased level in the sample from the subject being treated as compared to the first VEGF antibody control level and/or an equal level as compared to the second VEGF antibody control level is indicative for relapse, progression and/or mortality in the subject, and wherein an increased level in the sample from the subject being treated as compared to the second VEGF antibody control level and/or an equal level as compared to the first VEGF antibody control level is indicative for no relapse and no progression and no mortality in the subject.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the cancer is an epithelial cancer, optionally selected from the group consisting of ovarian cancer, colorectal cancer, colon cancer, lung cancer, breast cancer, glioblastoma, kidney (renal) renal, pancreatic cancer, prostate cancer, gastric cancer, and liver cancer, preferably ovarian cancer.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the drug is an angiogenesis inhibitor or a chemotherapeutic drug, optionally a monoclonal antibody, optionally bevacizumab.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the anti-VEGF antibody is detected in an immunoassay.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the immunoassay is selected from the group of immunoprecipitation, enzyme immunoassay (EIA), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassay, a chemiluminescent assay, an agglutination assay, nephelometric assay, turbidimetric assay, a Western Blot, a competitive immunoassay, a noncompetitive immunoassay, a homogeneous immunoassay a heterogeneous immunoassay, a bioassay and a reporter assay optionally a luciferase assay or luminex.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the sample is plasma or serum.

### Claim 12 (depends on 1)

The method according to claim 1 comprising
(a) contacting the sample with vascular endothelial growth factor (VEGF) or an antigenic peptide fragment thereof under conditions allowing for formation of a complex between anti-VEGF antibodies with VEGF or a peptide fragment thereof,
(b) detecting the complex.

### Claim 13

An immunoassay method for detecting an anti-VEGF antibody in a sample from a subject, comprising
(a) contacting the sample suspected of comprising an anti-VEGF antibody with vascular endothelial growth factor (VEGF) or an antigenic peptide fragment thereof under conditions allowing for formation of a complex between the anti-VEGF antibody with VEGF or the peptide fragment thereof,
(b) detecting the complex.

### Claim 14 (depends on 12)

The method of claim 12, wherein the VEGF or the peptide fragment thereof is immobilized on a surface.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the complex is detected using a secondary antibody against the Fc portion of the anti-VEGF antibody.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the anti-VEGF antibody is an IgG-antibody and the secondary antibody is an anti-IgG antibody.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the secondary antibody is labeled with a detectable marker.

### Claim 18 (depends on 1)

The method of claim 1, wherein the presence of one or more further markers for cancer is detected in the sample.

### Claim 19

VEGF or an antigenic peptide fragment thereof for diagnosis of cancer or for prediction of response of a subject suffering from cancer and to treatment with a drug, or for prediction of relapse and/or mortality of a subject suffering from cancer and to be treated with a drug.

### Claim 20 (depends on 3)

An angiogenesis inhibitor for use in the treatment of cancer in a subject, wherein the angiogenesis inhibitor is administered to the subject when the subject is predicted as responding to said treatment by a method according to claim 3.

### Claim 21

An angiogenesis inhibitor for use in the treatment of cancer in a subject, wherein the angiogenesis inhibitor is administered when the level anti-VEGF antibodies in a sample from the subject is above 8 units/ml.

### Claim 22 (depends on 20)

The angiogenesis inhibitor for use according to claim 20, wherein the angiogenesis inhibitor is bevacizumab.

### Claim 23 (depends on 20)

The angiogenesis inhibitor for use according to claim 20, wherein the cancer is a VEGF or VEGF-receptor (VEGFR) associated cancer, optionally ovarian cancer.

### Claim 24

A kit for diagnosing cancer, or predicting response of a cancer patient to treatment with an angiogenesis inhibitor or a chemotherapeutic drug, said kit comprising VEGF or an antigenic peptide thereof, and means to detect antibodies binding to said VEGF or peptide thereof.
